# Alpha Nuclide

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alpha-nuclide

- Industry: Biotechnology
- Headquarters: Ningbo, China
- Website: www.astathera.com
- Latest round: Series A (Feb 17, 2026)
- Investors on record: 4

## About

Based in Ningbo, China and founded in 2020, Alpha Nuclide (Ningbo) Medical Technology Co., Ltd., trading as Alpha Nuclide, is a drug developer dedicated to nuclide drug research. It has a R&D center in Hangzhou. The co-founder and CEO of the company, Yutian Feng, graduated from Duke University. The co-founder and chief adviser, Michael Zalutsky, is a professor at Duke University Medical Center and the founder of Cereius Inc. The core technical team comes from universities and research institutions such as the University of Pennsylvania and Brookhaven National Laboratory. In February 2026, Alpha Nuclide closed Series A+ funding from new investors HCH Capital, Duce Capital, Finnova Capital, with participation from returning investor Coastal Industry Investment.

The company's research areas include radionuclide drugs, nuclide production, alpha & beta nuclide comparison, and alpha nuclide comparison. It provides scientific research services and nucleide drug R&D contract outsourcing services to pharmaceutical companies, hospitals and colleges. The product pipelines cover liver cancer, lung cancer, breast cancer, and other tumor diseases. Asta Thera also supplies germanium-68, germanium-gallium generators, iodine-123, copper-64, thallium-201, and other new medical nuclides.
The company generates revenue by providing scientific research services and nucleus drug research and development contract outsourcing services, as well as conducting nucleide drug research.

## Funding rounds

- Series A, Feb 17, 2026 — Duce Capital, HCH Capital, Finnova Capital, Coastal Industry Investment
- Series A, Jul 29, 2025 — Coastal Industry Investment

## Investors

- Coastal Industry Investment (https://capitalatlas.ai/funds/coastal-industry-investment) — Series A
- Duce Capital (https://capitalatlas.ai/funds/duce-capital) — Series A
- HCH Capital (https://capitalatlas.ai/funds/hch-capital) — Series A
- Finnova Capital (https://capitalatlas.ai/funds/finnova-capital) — Series A